John Michael Kane MD
Psychopharmacology
Professor, The Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research. Vice President, Behavioral Health Services, Northwell Health. Chairman, Department of Psychiatry, The Zucker Hillside Hospital. Chair & Professor, Psychiatry, Hofstra Northwell School of Medicine. Professor, Molecular Medicine, Hofstra Northwell School of Medicine.
Join to View Full Profile
75-59 263rd StreetKaufman Building, Suite 103Glen Oaks, NY 11004
Phone+1 718-470-8141
Dr. Kane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Kane is a psychiatrist in Glen Oaks, NY and is affiliated with multiple hospitals in the area, including Long Island Jewish Medical Center, Glen Cove Hospital, and The Zucker Hillside Hospital. He received his medical degree from NYU Grossman School of Medicine and has been in practice 46 years. He specializes in psychopharmacology and is experienced in bipolar disorder, depression, schizophrenia, mood disorders, and anxiety disorders.
Education & Training
Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalResidency, Psychiatry, 1971 - 1975
New York University School of MedicineClass of 1971
Certifications & Licensure
NY State Medical License 1972 - 2027
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. Start of enrollment: 2013 Feb 01
Publications & Presentations
PubMed
- Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.John M Kane, Orna Tohami, Kelli R Franzenburg, Mark Suett, Nir Sharon
CNS Drugs. 2026-02-01 - Do early intervention services for psychosis maintain their effects after transition to usual/modular care? A systematic review and meta-analysis.Gonzalo Salazar de Pablo, Joao Almeida, Jesus Camacho, José Suárez Campayo, Ana Catalan
World Psychiatry. 2026-02-01 - Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.John M Kane, Orna Tohami, Kelli R Franzenburg, Mark Suett, Nir Sharon
CNS Drugs. 2026-02-01
Journal Articles
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase SchizophreniaJohn M Kane, Eric D Achtyes, Delbert G Robinson, JAMA Psychiatry
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel DatasetJohn Kane, MD, JMIR Medical Education
- Disturbing Lack of Early Intervention Studies in Bipolar Disorder—ReplyJohn Kane, MD, JAMA
Authored Content
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase SchizophreniaJuly 2020
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel DatasetDecember 2018
Press Mentions
International Schizophrenia Experts Develop Consensus Criteria for RelapseOctober 9th, 2025- Sunny Tang, MD: Decoding Speech Patterns to Improve Psychiatric CareMay 15th, 2025
- Teva to Present Data Demonstrating UZEDYtm (Risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual MeetingMay 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
